Vera Therapeutics, Inc. (VERA) on Monday announced the appointment of Dr. Robert M. Brenner as the new Chief Medical Officer, replacing Dr. Celia Lin, and William D. Turner as the new Chief Development Officer, effective immediately to help lead the development of the company's late-stage product candidate, atacicept currently in Phase 3 clinical trial for IgA nephropathy (IgAN).
Dr. Brenner is a nephrologist and biotechnology executive with over 25 years of experience. Previously, he held executive positions in several clinical-stage biotech companies, including Chief Medical Officer at Orionis Biosciences and SVP of Medical Affairs at AMAG Pharmaceuticals, where he helped the latter achieve its first therapeutic approval and introduced Feraheme for the treatment of iron deficiency anemia.
Meanwhile, Turner has developed and marketed drugs for nearly thirty years. He has overseen several companies through all stages of clinical program development and product development, multiple filings for drug applications, and the creation and transition of several crucial commercialization procedures. Before joining Vera, Turner was the Chief Regulatory and Technical Operations Officer at Sierra Oncology
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.